Cargando…

LAG-3 Blockade with Relatlimab (BMS-986016) Restores Anti-Leukemic Responses in Chronic Lymphocytic Leukemia

SIMPLE SUMMARY: Patients with chronic lymphocytic leukemia (CLL), the most frequent B cell malignancy in western countries, develop a progressive immunosuppression, leading to diminished anti-tumor immunity. Within the last years, immune checkpoint blockade has revolutionized anti-cancer therapies....

Descripción completa

Detalles Bibliográficos
Autores principales:	Sordo-Bahamonde, Christian, Lorenzo-Herrero, Seila, González-Rodríguez, Ana P., Payer, Ángel R., González-García, Esther, López-Soto, Alejandro, Gonzalez, Segundo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8123840/ https://www.ncbi.nlm.nih.gov/pubmed/33925565 http://dx.doi.org/10.3390/cancers13092112

Ejemplares similares

Ig-Like Transcript 2 (ILT2) Blockade and Lenalidomide Restore NK Cell Function in Chronic Lymphocytic Leukemia
por: Villa-Álvarez, Mónica, et al.
Publicado: (2018)

BTLA/HVEM Axis Induces NK Cell Immunosuppression and Poor Outcome in Chronic Lymphocytic Leukemia
por: Sordo-Bahamonde, Christian, et al.
Publicado: (2021)

Mechanisms of Apoptosis Resistance to NK Cell-Mediated Cytotoxicity in Cancer
por: Sordo-Bahamonde, Christian, et al.
Publicado: (2020)

Immunoglobulin‐like transcript 2 blockade restores antitumor immune responses in glioblastoma
por: Lorenzo‐Herrero, Seila, et al.
Publicado: (2022)

Immunosurveillance of cancer cell stress
por: Lorenzo-Herrero, Seila, et al.
Publicado: (2019)

BTLA dysregulation correlates with poor outcome and diminished T cell-mediated antitumor responses in chronic lymphocytic leukemia
por: Sordo-Bahamonde, Christian, et al.
Publicado: (2023)

Mechanisms of Resistance to NK Cell Immunotherapy
por: Sordo-Bahamonde, Christian, et al.
Publicado: (2020)

The Mithralog EC-7072 Induces Chronic Lymphocytic Leukemia Cell Death by Targeting Tonic B-Cell Receptor Signaling
por: Lorenzo-Herrero, Seila, et al.
Publicado: (2019)

Driver Mutations and Single Copy Number Abnormalities Identify Binet Stage A Patients with Chronic Lymphocytic Leukemia with Aggressive Progression
por: Gonzalez-Rodriguez, Ana P., et al.
Publicado: (2020)

NK Cell-Based Immunotherapy in Cancer Metastasis
por: Lorenzo-Herrero, Seila, et al.
Publicado: (2018)

NK Cells in the Treatment of Hematological Malignancies
por: Gonzalez-Rodriguez, Ana P, et al.
Publicado: (2019)

Preclinical Characterization of Relatlimab, a Human LAG-3–Blocking Antibody, Alone or in Combination with Nivolumab
por: Thudium, Kent, et al.
Publicado: (2022)

Chemo-Immunotherapy: A New Trend in Cancer Treatment
por: Sordo-Bahamonde, Christian, et al.
Publicado: (2023)

Neoadjuvant relatlimab and nivolumab in resectable melanoma
por: Amaria, Rodabe N., et al.
Publicado: (2022)

The Latest Option: Nivolumab and Relatlimab in Advanced Melanoma
por: Albrecht, Lea Jessica, et al.
Publicado: (2023)

Beyond the anti-PD-1/PD-L1 era: promising role of the BTLA/HVEM axis as a future target for cancer immunotherapy
por: Sordo-Bahamonde, Christian, et al.
Publicado: (2023)

Author Correction: Neoadjuvant relatlimab and nivolumab in resectable melanoma
por: Amaria, Rodabe N., et al.
Publicado: (2023)

Lenalidomide and Chronic Lymphocytic Leukemia
por: González-Rodríguez, Ana Pilar, et al.
Publicado: (2013)

The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab
por: Mallardo, Domenico, et al.
Publicado: (2023)

Dapagliflozin: BMS 512148; BMS-512148
Publicado: (2012)

Expansion of NK Cells and Reduction of NKG2D Expression in Chronic Lymphocytic Leukemia. Correlation with Progressive Disease
por: Huergo-Zapico, Leticia, et al.
Publicado: (2014)

Lenalidomide Induces Immunomodulation in Chronic Lymphocytic Leukemia and Enhances Antitumor Immune Responses Mediated by NK and CD4 T Cells
por: Acebes-Huerta, Andrea, et al.
Publicado: (2014)

Crystal structures of trimeric HIV Env with entry inhibitors BMS-378806 and BMS-626529
por: Pancera, Marie, et al.
Publicado: (2017)

Barrel-muon-spectrometer: BMS
Publicado: (2005)

Barrel-muon-spectrometer: BMS
Publicado: (2005)

Barrel-muon-spectrometer: BMS
Publicado: (2005)

Barrel-muon-spectrometer: BMS
Publicado: (2005)

Barrel-muon-spectrometer: BMS
Publicado: (2005)

Barrel-muon-spectrometer: BMS
Publicado: (2005)

Barrel-muon-spectrometer: BMS
Publicado: (2005)

The Emerging Role of NK Cells in Immune Checkpoint Blockade
por: Martinez-Perez, Alejandra, et al.
Publicado: (2022)

Construction of the MPI BMS Prototype Chamber
por: Bratzler, U, et al.
Publicado: (1997)

BMS-708163 and Nilotinib restore synaptic dysfunction in human embryonic stem cell-derived Alzheimer’s disease models
por: Nishioka, Hisae, et al.
Publicado: (2016)

Differentiation Between Sarcomatous and Leukemic Lymphocytes in Mice
por: Kirschbaum, A., et al.
Publicado: (1940)

Gingival Leukemic Infiltration in Chronic Lymphocytic Leukemia
por: Kacem, Karima, et al.
Publicado: (2019)

Cystatin C-Based Equations Detect Hidden Kidney Disease and Poor Prognosis in Newly Diagnosed Patients with Multiple Myeloma
por: Cepeda-Piorno, Francisco-Javier, et al.
Publicado: (2022)

BMS1 Is Mutated in Aplasia Cutis Congenita
por: Marneros, Alexander G.
Publicado: (2013)

Abscopal effect observed in visceral and osseous metastases after liver SBRT in combination with nivolumab and relatlimab for sinonasal mucosal melanoma—a case report
por: Cerbon, Danielle, et al.
Publicado: (2023)

Role of Mitochondrial Toxicity in BMS-986094-Induced Toxicity
por: Feng, Joy Y., et al.
Publicado: (2017)

Effect of BMS-470539 on lipopolysaccharide-induced neutrophil activation
por: Lee, Seongheon, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1gcnco6bf4u6u20pcqh27ona5o